The progression of 102 Brazilian patients with bipolar disorder: outcome of first 12 months of prospective follow-up

A evolução de 102 pacientes brasileiros com transtorno bipolar: os primeiros 12 meses de acompanhamento prospectivo

Fernanda Novis,1 Patricia Cirillo,1 Rafael Assis da Silva,1 Ana Letícia Santos,1 Luciana Angélica Silva Silveira,1 Adriana Cardoso,1 Pedro Coscarelli,2 Antônio Egidio Nardi,1 Elie Cheniaux3

Abstract

Introduction: Prospective studies have shown that the course of bipolar disorder (BD) is characterized by the persistence of symptoms, predominantly depression, along most of the time. However, to our knowledge, no studies in Latin America have investigated it.

Objectives: To replicate international studies using a Brazilian sample to prospectively analyze treatment outcomes in the first year and to determine potential chronicity factors.

Methods: We followed up 102 patients with BD for 12 months and evaluated the number of months with affective episodes and the intensity of manic and depressive symptoms using the Young Mania Rating Scale (YMRS) and the Hamilton Depression Scale (HAM-D17). Sociodemographic and retrospective clinical data were examined to determine possible predictors of outcome.

Results: Almost 50% of the patients had symptoms about half of the time, and there was a predominance of depressive episodes. Disease duration and number of depressive episodes were predictors of chronicity. Depressive polarity of the first episode and a higher number of depressive episodes predicted the occurrence of new depressive episodes.

Conclusion: In general, BD outcome seems to be poor in the first year of monitoring, despite adequate treatment. There is a predominance of depressive symptoms, and previous depressive episodes are a predictor of new depressive episodes and worse outcome.

Keywords: Clinical progression, outcome assessment, depression, bipolar disorder.

Resumo

Introdução: Estudos prospectivos vêm demonstrando que o curso do transtorno bipolar (TB) é marcado por uma persistência de sintomas em grande parte do tempo, sendo estes predominantemente depressivos. Porém, até onde sabemos, não há estudos na América Latina sobre o assunto.

Objetivo: Replicar pesquisas internacionais com uma amostra brasileira, para estudar prospectivamente a evolução no primeiro ano de tratamento e possíveis fatores relacionados a cronicidade.

Método: Acompanhamos 102 pacientes com TB mensalmente por 12 meses, avaliando o número de meses em episódios afetivos e a intensidade dos sintomas maníacos e depressivos com a Young Mania Rating Scale (YMRS) e a Hamilton Depression Scale (HAM-D17), respectivamente. A partir de dados sociodemográficos e clínicos retrospectivos, buscamos definir fatores preditivos de evolução.

Resultados: Quase metade dos pacientes ficou cerca de metade do tempo sintomática, com predominância de episódios depressivos. Fatores preditivos de cronicidade encontrados foram a duração da doença e o número prévio de episódios depressivos. Encontramos, ainda, como fatores que predizem a ocorrência de novos episódios depressivos, a polaridade depressiva do primeiro episódio e um número maior de episódios depressivos.

Conclusões: Em geral, a evolução do TB é bastante insatisfatória no primeiro ano de acompanhamento, apesar de tratamento adequado, com a predominância de sintomas depressivos. Episódios depressivos prévios são um fator preditivo de novos episódios depressivos e de uma pior evolução.

Descritores: Evolução clínica, avaliação de resultados, depressão, transtorno bipolar.
Introduction

Kraepelin described what we now call bipolar disorder (BD) as a periodic disease with symptom-free intervals and a good outcome. However, recent studies have suggested that the reality is substantially different. Prospective studies with large samples have shown that BD is characterized by a chronic course, persistence of symptoms for most of the time and frequent recurrence despite adequate treatment.

Moreover, although the diagnosis is made after a manic episode, there is a predominance of depressive symptoms along the course of the disease. These symptoms have a subsyndromal intensity most of the times, which has been associated with the impact that BD has, particularly on occupational and social functioning.

Several longitudinal prospective studies have already investigated the course of BD, but most included American and European samples, and, to our knowledge, no similar studies have been conducted in Latin America. Therefore, we prospectively evaluated the progression in the first year of follow-up of 102 Brazilian patients with BD in a university outpatient department. The occurrence of affective episodes and the intensity of manic and depressive symptoms were evaluated, as well as the occurrence of psychotic symptoms. At the same time, demographic data and retrospective clinical records were examined to determine possible predictive factors of chronicity. By replicating studies conducted in other continents, this study examined clinical outcomes and predictive factors in a Brazilian sample of patients and compared them to those found in international studies.

Methods

Sample

This study, conducted in the BD outpatient research department of the Psychiatry Institute of Universidade Federal do Rio de Janeiro (UFRJ), was approved by the Ethics in Research Committee of that institution on November 23, 2007.

Our BD outpatient research department sees patients referred internally, that is, who had been hospitalized in wards in the same Institute, and externally, who were referred by other services or who sought help directly in our service. The diagnosis of BD and psychiatric comorbidities is made according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR), using a semi-structured interview, the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), always conducted by the same examiner. Only BD types I and II are included in outpatient follow-up programs. Other exclusion criteria were: age below 18 years, serious non-psychiatric disease and refusal to sign the consent term. Therefore, patients with psychiatric comorbidities, as well as pregnant and postpartum women, were also included. This study recruited new patients, enrolled in our service from October 2002 to March 2010.

Clinical evaluation

The patients were treated in a naturalistic follow-up with monthly visits. Prescribed medications were those dispensed by the Institute’s pharmacy whenever possible. A structured open interview was used to collect demographic and retrospective clinical data for each patient: age at onset; time to diagnosis; duration of the disease; number of hospitalizations and previous manic and depressive episodes; psychotic symptoms and psychotic events; polarity of first episode (depression, mania, mixed, psychosis); maternal death before age 11 years; and number of suicide attempts. The following data were separated into categories according to number of events (one, two, three, four, five to nine, ten or more): hospitalizations; depressive, manic and mixed episodes; psychotic events; and suicide attempts. This classification was used because patient recall and reports were inaccurate when there were more than four events.

Every month, each patient was evaluated by the same examiner, the assisting physician, to ensure reliability. Moreover, each physician was previously trained by the senior investigator to use the Young Mania Rating Scale (YMRS) and the Hamilton Depression Scale (HAM-D17). However, interexaminer agreement was not evaluated. The number of months with euthymic, manic, depressive and mixed moods was defined according to the DSM-IV-TR criteria; manic symptoms were evaluated using the YMRS and depressive symptoms, the HAM-D17. The mixed state months were conventionally defined as those when the patient had at least two manic symptoms and at least two depressive symptoms. Months of euthymic mood were those when the criteria to define manic and major depressive episodes were not met.

The other outcome measures were intensity of manic and depressive symptoms, according to the monthly application of the YMRS and the HAM-D17. Mean total scores were calculated for the 12 months of follow-up for each patient. In addition, time free of psychotic symptoms was defined according to clinical observation.

Finally, we studied whether the outcomes of prospective follow-up were associated or correlated with sociodemographic data or clinical history to determine possible predictive factors of chronicity.
Statistical analysis

The Pearson product-moment correlation was used to analyze continuous variables: age, education, age at onset, time to diagnosis and disease duration. The nonparametric Mann-Whitney U test was used for the comparison between groups according to sex, maternal death before age 11 years and previous psychotic symptoms. The Kruskal-Wallis test, followed by post-hoc analyses when an association was detected, compared variables according to multiple categories: marital status; number of manic, depressive and mixed episodes; polarity of first episode; and number of hospitalizations.

A model of generalized linear regression was built for each outcome variable (months with euthymic, manic and depressive moods) and for the scores of manic (YMRS) and depressive (HAM-D17) symptoms. A Poisson distribution was assumed for the outcome variables, and a normal distribution, for symptom scores. The independent variables in each multivariate model were those that had a marginally significant association ($p \leq 0.10$) in univariate analysis.

The level of significance was set at $p < 0.05$ for all the study, with no adjustment for multiple analyses.

Results

During the study, 102 patients were selected and completed the monthly follow-up during 12 months. Only six had BD type II. A total of 144 patients were excluded because they did not keep regular medical visits.

The sample of excluded patients was characterized by a lower educational level (Mann-Whitney test: $p < 0.001$) than that of the patients that remained in the study. There was a marginally significant difference in age, marital status and hospitalizations: the patients excluded were younger (Mann-Whitney test: $p = 0.053$), more frequently single (Kruskal-Wallis test: $p = 0.087$) and had fewer hospitalizations (Kruskal-Wallis test: $p = 0.067$). There were no significant differences in sex, years of schooling, family history, age at onset, diagnosis duration and time to diagnosis.

Sample characteristics and retrospective clinical data

Table 1 shows the demographic and retrospective clinical data of the 102 patients that completed the 12-month follow-up. Our sample comprised a large number of women, and there was a broad variation in age; the level of education was relatively high, as most patients has at least 11 years of schooling; and less than 50% of the patients had a partner.
The progression of Brazilian bipolar patients - Novis et al.

Clinical progression

The drugs prescribed during the prospective 12-month follow-up were: lithium, 65.7% (n = 67); anticonvulsants (valproic acid, carbamazepine, oxcarbazepine, lamotrigine or topiramate), 67.6% (n = 69); antidepressants, 41.2% (n = 42); antipsychotics, 77.5% (n = 79); benzodiazepines, 68.6% (n = 70); and thyroid hormone, 9.8% (n = 10). No patient underwent electroconvulsive therapy.

Table 2 shows total time with euthymic, manic and depressive symptoms in the group of 102 patients during the 12-month follow-up, as well as the duration of psychotic symptoms.

Only 5.8% (n = 6) of the participants remained euthymic along all the 12 months, whereas 21.6% (n = 22) had symptoms during all the study. A total of 43.1% were symptomatic for at least half of the time. Patients remained euthymic for a mean 4.9±4.1 months.

Depressive symptoms were felt at some time by 75.5% (n = 77) of the patients; in 6.9% (n = 7), they occurred for at least half of all the study time. The patients had depressive symptoms for a mean 3.6±3.5 months.

Manic symptoms were felt by 54.9% (n = 56) of the participants; 6.9% (n = 7) of the patients had manic symptoms at least half of all the study time. No patients had manic symptoms during all the 12 months: mean time with manic symptoms was 1.7±2.3 months.

The evaluation of the intensity of the manic symptoms revealed that the mean YMRS score in the whole sample was 5.2±4.3. The mean HAM-D17 score of intensity of depressive symptoms was 6.8±4.8.

Mixed moods were found at some time in 49% (n = 50) of the patients, and 11.8% (n = 12) persisted for at least half of the study time. The patients had depressive symptoms for a mean 1.3±2.4 months.

The analysis of polarity of first episode revealed that patients were divided practically equally between depression and mania. About one fourth of the patients had already had psychotic symptoms, but only a small percentage had pure psychotic episodes, that is, not concurrent with affective symptoms. Finally, almost one fourth of all participants had already had at least one suicide attempt.

Comorbidities were found in 43.1% of the patients (n = 44): obsessive compulsive disorder (13.7%; n = 14), social (12.8%; n = 13) and specific (9.8%; n = 10) phobias, panic disorder (9.8%; n = 10), mostly associated with agoraphobia (n = 7), eating disorders (7.8%; n = 8), alcohol abuse and dependence (7.8%; n = 8 - abuse: n = 4; dependence: n = 4); cocaine abuse and dependence (5%; n = 5 - abuse: n = 4; dependence: n = 2), generalized anxiety disorder (2.9%; n = 3), post-traumatic stress disorder (2.9%; n = 3), epilepsy (2%; n = 2), somatoform disorder (1%; n = 1), and conversion disorder (1%; n = 1).

Previously taken medication included: lithium (56.9%; n = 58) anticonvulsants (valproic acid, carbamazepine, oxcarbazepine, lamotrigine or topiramate) (78.4%; n = 80), antidepressants (60.8%; n = 62), antipsychotics (76.5%; n = 78) and benzodiazepines (69.6%; n = 71). Nine patients (8.8%) had undergone electroconvulsive therapy, and 21.5% (n = 22) had not undergone any previous treatment.

Factors associated with progression

Total euthymic time during the prospective 12-month follow-up had a negative correlation with total disease duration (r = -0.23; p = 0.02). In contrast, a greater number of previous depressive episodes was associated with a shorter euthymic time (χ² = 16.24; gl = 6; p = 0.01). In multivariate analysis, only high number of previous depressive episodes was associated with total euthymic time (p = 0.0006).
A longer total depression time in the prospective evaluation was strongly associated with a higher number of previous depressive episodes ($\chi^2 = 25.87; \text{gl} = 6; p = 0.002$) and depressive polarity of the first episode ($\chi^2 = 7.44; \text{gl} = 1; p = 0.006$), as well as with female sex (U test; $p = 0.03$) and maternal death before age 11 years (U test; $p = 0.04$). In multivariate analysis, number of previous depressive episodes ($p < 0.0001$), female sex ($p = 0.002$) and maternal death before age 11 years ($p = 0.005$) remained statistically significant.

The intensity of depressive symptoms according to the HAM-D17 scores was positively correlated with total disease duration ($r = 0.20; p = 0.04$) and negatively correlated with age at onset ($r = -0.21; p = 0.04$). Moreover, a higher intensity of depressive symptoms was associated with a greater number of previous depressive episodes ($\chi^2 = 13.61; \text{gl} = 6; p = 0.03$) and female sex (U test; $p = 0.01$). In multivariate analysis, only number of previous depressive episodes ($p = 0.005$) remained statistically significant.

In univariate analysis, no variables were correlated or associated with total time of manic episodes. Multivariate analysis using variables with marginal significance (marital status and number of previous depressive episodes) revealed that being married ($p = 0.0002$) or divorced ($p = 0.001$) had a negative correlation with total manic time (single was the reference category). Greater intensity of manic symptoms according to YMRS scores was strongly associated with a higher number of previous manic episodes ($\chi^2 = 19.48; \text{gl} = 5; p = 0.002$). As only one variable was statistically significant (including marginal significance), there was no need to conduct a multivariate analysis.

Finally, no variables had any correlation or association with total time in mixed mood or total time of psychotic symptoms.

### Discussion

Our study evaluated the clinical progression of 102 patients with BD during the first 12 months of their follow-up in an outpatient research department. Almost half of the patients had affective episodes during most of the time, and about one fifth of the sample had no recovery at any time during the 12 months. The depressive episodes were the most frequent and persistent. About three fourths of the patients had some depressive episode, whereas a little more than half of the sample had some manic episode. Time spent in depression was a mean twice the time in manic or mixed moods. The mean intensity of both depressive and manic symptoms was low, but there were very broad individual variations. In average, psychotic symptoms affected fewer than half of the patients and lasted a shorter period of time.

Other authors also found that symptoms persisted for a significant length of the course of the disease.2,4,8,9 Judd et al.2 prospectively followed up 146 patients with BD type I for 12 to 20 years and found that the patients remained asymptomatic for half of the disease course. Moreover, subsyndromal symptoms were present for a longer time than full affective episodes. Post et al.3 followed up 258 patients with BD, most type I, for one year and found that almost half (40.7%) of the patients was moderately ill (symptomatic for more than 25% and less than 75% of the follow-up time) and more than one fourth were severely ill (symptomatic for more than 75% of the time). For two years, Perlis et al.4 followed up 1,469 patients, who received "the best possible treatment". Despite that, only a little more than half of the sample achieved recovery, and of those who did, almost half had recurrences.

Still in agreement with our findings, the predominance of depressive symptoms over manic and mixed moods along the course of the disease has also been reported in other studies.2,4,8,9 and some authors found that psychotic symptoms are not very frequent.2,13 In our study, a longer
time with affective episodes during the prospective 12-month follow-up was correlated with a longer disease duration and associated with a higher number of previous depressive episodes. Total depressive time, in turn, was strongly associated with number of previous depressive episodes, and the occurrence of depressive polarity of first episode; it was also associated with female sex and maternal death before age 11 years. Longer disease duration, lower age at onset, more previous depressive episodes, depressive polarity of first episode and female sex were predictive of more intense depressive symptoms. Total manic time was not correlated or associated with any sociodemographic or retrospective clinical data, which may be explained by the fact that our patients had a shorter percentage of manic time. However, a greater number of previous manic episodes was strongly predictive of more severe manic symptoms during the prospective 12-month follow-up. Total time of psychotic symptoms was also not correlated with any variable, possibly because psychotic symptoms were observed for only a short time.

Several outcome factors found in our study have also been reported by other authors: number of previous affective episodes, depressive polarity of first episode, female sex, disease duration and early onset. Other authors have suggested that previous depressive episodes might predict a progression with more depressive symptoms, whereas previous manic episodes might predict a progression with more manic symptoms. In this sense, Nolen et al. found that a greater intensity of depressive and manic symptoms is associated with a high number of previous depressive and manic episodes. Daban et al., however, found that, in agreement with our findings, depressive polarity of first episode was a good predictor of greater chronicity and of predominance of depressive polarity of subsequent episodes.

Therefore, greater attention has been drawn to the theory created by Angst, of a polarity predominance in patients with BD. According to that theory, some patients tend to have twice or more manic than depressive episodes, whereas the opposite is true for some other patients. Such type of predominance seems to be found in about half of the patients with BD. Still according to that theory, the predominance of depressive episodes is more frequent than that of manic episodes and is be associated with poorer outcomes.

Differently from other studies, we did not find any correlation between outcome and psychotic symptoms or number of previous hospitalizations. However, contradictions about which factors predict outcomes are frequent in the literature. The major reason of this inconsistency has been linked to method differences, as there are different criteria to define a poor outcome, such as total symptomatic time, time to recurrence and others.

One of the limitations of our study was the severity of patient disease, as they were followed up in a BD outpatient research department. Therefore, our sample may fail to represent all individuals that have BD. In our outpatient research department, we see seriously affected patients referred by other institutions, as well as patients referred directly after hospitalization. In contrast, a large number of the patients under treatment were excluded from the sample because they did not keep the monthly attendance to visits during the study time. We believe that some of them were patients with more severe disease. Therefore, as this sample excluded a large number of patients that were not able to keep their regular follow-up, the patients selected may not represent the population of interest, a fact that may affect the internal validity of this study. Moreover, the patients excluded from the study had a lower socioeconomic status than those that were included, which may complicate the generalization of our study findings for this population.

Another limitation was the fact that it was a naturalistic investigation and the follow-up time, only 12 months, was short. However, other longitudinal studies that conducted evaluations of up to 20 years reported similar results, which confirms certain constancy along time. Finally, the sample was very heterogeneous, and there were great variations in retrospective clinical data (age, age at onset, time to diagnosis and disease duration). This may have interfered with the adequate evaluation of factors that predicted outcome, which indicates that studies should separate participants into more homogenous groups and conduct more careful analyses of the interference of individual factors.

Moreover, numerous participants had been ill for a long time and might have experienced several different approaches to treatment, which may determine poorer patient progression than more recent disease and more adequate treatment approaches.

**Conclusion**

In agreement with other studies, our findings showed that BD outcomes seem to be poor, even when the patients are followed up in research centers and comply with treatment adequately. A large percentage of patients had affective episodes, particularly depressive events in most of the time. We also found that disease duration and previous number of depressive episodes are factors that predict a poor prognosis. Finally, our results confirm findings that depressive polarity of first episode
and higher number of previous depressive episodes predict the occurrence of new depressive episodes and their greater intensity. Therefore, more effective BD treatments should be developed, particularly for the management of depressive episodes, as they seem to have a greater impact on outcome. In the same line, we plan future studies to investigate the occurrence of polarity predominance during the course of the disease and to evaluate factors that predict outcome in subgroups according to retrospective clinical differences.

**References**


**Correspondence:**

Fernanda Novis
Av. das Américas, 3333, sala 410, Barra da Tijuca
22631-003 - Rio de Janeiro, RJ - Brazil
Tel./Fax: +55-21-2497-3435
E-mail: novisfernanda@gmail.com

**Trends Psychiatry Psychother. 2013;XX(X) – X**